AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 30651138
Drug: Celecoxib 200
RxNorm normalized name: celecoxib 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib 200 mg once daily for 2 weeks
Trial: 30651138
Drug: Placebo 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 200 mg once daily for 2 weeks
Trial: 23014927
Drug: Intravenous atrial
RxNorm normalized name: Echinacea, aerial parts
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous atrial natriuretic peptide (ANP) at 0.03 μg/kg/min
Trial: 23014927
Drug: Intravenous nitroglycerin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous nitroglycerin (NTG) at 0.3 μg/kg/min
Trial: 16796836
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline and heparin (Control)
Trial: 12697853
Drug: Bestatin (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bestatin (30 mg daily for 2 years)
Trial: 12504395
Drug: Placebo (daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (daily for 2 years)
Trial: 9117020
Drug: ABT‐761 (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT‐761 (200 mg)
Trial: 3537093
Drug: Individually polymerized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individually polymerized grass (IPG) immunotherapy with an accelerated dosage schedule (24,000 PNU over 9 weekly visits)
Trial: 3537093
Drug: Individually polymerized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individually polymerized grass (IPG) immunotherapy
Trial: 27733403
Drug: 10 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 μg vitamin D3/d supplementation for 20 weeks
Trial: 27733403
Drug: 20 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 μg vitamin D3/d supplementation for 20 weeks
Trial: 27733403
Drug: 0 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 μg vitamin D3/d (placebo) for 20 weeks
Trial: 18789844
Drug: Ondansetron (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron (8 mg/day)
Trial: 24850229
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups received fluvoxamine (100 mg/day for the first 4 weeks, then 200 mg/day for the rest of the trial)
Trial: 22885123
Drug: Phacoemulsification and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phacoemulsification and intraocular lens implant (phaco/IOL)
Trial: 18192132
Drug: daily‐dose blister
FDA approved: no
EMA approved: no
PMDA approved: no
Description: daily‐dose blister packaging (Pill Calendar)
Trial: 18192132
Drug: traditional bottles
RxNorm normalized name: danicopan
DrugBank: Danicopan (DB15401)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: traditional bottles of loose tablets
Trial: 776090
Drug: Fluocinolone acetonide
RxNorm normalized name: Fluocinolone Acetonide
DrugBank: Fluocinolone acetonide (DB00591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluocinolone acetonide cream
Trial: 21975580
Drug: THC (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: THC (500 μg/kg body weight)
Trial: 16019368
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg testosterone gel
Trial: 16019368
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg testosterone gel
Trial: 16019368
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg testosterone gel
Trial: 8027217
Drug: Alprazolam (APZ)
RxNorm normalized name: Alprazolam
DrugBank: Alprazolam (DB00404)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alprazolam (APZ) 2 mg orally
Trial: 2692094
Drug: Ofloxacin (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ofloxacin (200 mg tid for 10 days)
Trial: 2692094
Drug: Amoxycillin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxycillin (1 g tid for 10 days)
Trial: 31522785
Drug: l-arginine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: l-arginine infusion (1.2 μmol kg-1 min-1)
Trial: 28796316
Drug: Tocilizumab (TCZ)
RxNorm normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tocilizumab (TCZ) 8 mg/kg
Trial: 11928800
Drug: Vaccine therapy
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine therapy
Trial: 16006888
Drug: Nilutamide (antiandrogen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nilutamide (antiandrogen therapy)
Trial: 16006888
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy (vaccine + nilutamide)
Trial: 16006888
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy (vaccine + nilutamide) after vaccine arm progression
Trial: 12094191
Drug: Heparin dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin dosing of approximately 14 U/kg/h or an aPTT of approximately 70 seconds
Trial: 12094191
Drug: Heparin dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin dosing
Trial: 12094191
Drug: Heparin resistance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin resistance with high dosages and low aPTT values
Trial: 7670342
Drug: Millimetric electromagnetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Millimetric electromagnetic radiation (MER) therapy using wavelengths of 6.4 and 7.1 mm on a YAVOR device for 10 sessions
Trial: 7670342
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (specific drugs without MER therapy)
Trial: 7004051
Drug: Oral PGE2
RxNorm normalized name: PGE2
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral PGE2 (0.5 mg initially, followed by 1.0 mg every hour for up to 24 hours)
Trial: 7004051
Drug: Intravenous oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous oxytocin (starting at 5 mIU/min, increasing to 20 mIU/min)
Trial: 331402
Drug: Oral PGE2
RxNorm normalized name: PGE2
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral PGE2
Trial: 7004051
Drug: Both treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatments (PGE2 and oxytocin)
Trial: 25526906
Drug: Daidzein (500 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daidzein (500 mg/kg concentrate)
Trial: 23648344
Drug: Methylprednisolone (0.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylprednisolone (0.8 mg×kg(‐1)×d(‐1)) therapy
Trial: 21819161
Drug: Pantoprazole-Mg 40
RxNorm normalized name: pantoprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pantoprazole-Mg 40 mg once daily for 8 weeks
Trial: 21819161
Drug: Pantoprazole-Na 40
RxNorm normalized name: Pantoprazole Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pantoprazole-Na 40 mg once daily for 8 weeks
Trial: 21819161
Drug: Pantoprazole-Mg 40
RxNorm normalized name: pantoprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pantoprazole-Mg 40 mg once daily for 4 weeks
Trial: 21819161
Drug: Pantoprazole-Na 40
RxNorm normalized name: Pantoprazole Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pantoprazole-Na 40 mg once daily for 4 weeks
Trial: 10724056
Drug: Biweekly directly
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biweekly directly observed preventive therapy with a $5 monetary incentive
Trial: 10724056
Drug: Biweekly directly
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biweekly directly observed preventive therapy using a peer health adviser
Trial: 8956924
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of VGB and CBZ
Trial: 1551748
Drug: 4.5 mg
RxNorm normalized name: phenol 14.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4.5 mg slow‐release co‐dergocrine mesylate administered once daily for 6 weeks
Trial: 1551748
Drug: 4.5 mg
RxNorm normalized name: phenol 14.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4.5 mg slow‐release co‐dergocrine mesylate
Trial: 3873389
Drug: Oral, nonabsorbable
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral, nonabsorbable antibiotics (gentamicin + vancomycin + nystatin or neomycin + colistin + nystatin)
Trial: 3873389
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no oral, nonabsorbable antibiotics)
Trial: 3873389
Drug: Oral, nonabsorbable
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral, nonabsorbable antibiotics
Trial: 31618127
Drug: GC4419 90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GC4419 90 mg
Trial: 31618127
Drug: GC4419 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GC4419 30 mg
Trial: 27871280
Drug: Stereotactic radiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Stereotactic radiation therapy (n=55)
Trial: 20159245
Drug: All treatments
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All treatments (Budesonide, Nedocromil, Placebo)
Trial: 16080282
Drug: Fosfomycin trometamol
RxNorm normalized name: trometamol
DrugBank: Tromethamine (DB03754)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fosfomycin trometamol (FT) 3 g every 10 days for 6 months
Trial: 7702152
Drug: Pre-operative oral
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pre-operative oral fluids (water)
Trial: 363484
Drug: Celestone Chronodose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celestone Chronodose (subacromial injection)
Trial: 363484
Drug: Celestone Chronodose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celestone Chronodose (gluteal injection)
Trial: 31779925
Drug: Intensive blood
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive blood pressure reduction with diuretics
Trial: 31779925
Drug: Standard blood
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard blood pressure reduction with diuretics
Trial: 29872803
Drug: 3 g
RxNorm normalized name: Molds 3 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g high MW (HMW) barley β-glucan
Trial: 29872803
Drug: 5 g
RxNorm normalized name: 15 g/31 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 g low MW (LMW) barley β-glucan
Trial: 29872803
Drug: 3 g
RxNorm normalized name: Molds 3 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g low MW (LMW) barley β-glucan
Trial: 21130977
Drug: isosorbide mononitrate
RxNorm normalized name: Isosorbide Mononitrate
DrugBank: Isosorbide mononitrate (DB01020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: isosorbide mononitrate (ISMN) 60 mg
Trial: 21130977
Drug: losartan 100
RxNorm normalized name: LOSARTAN 100MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: losartan 100 mg + ISMN 15 mg
Trial: 21130977
Drug: losartan 100
RxNorm normalized name: LOSARTAN 100MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: losartan 100 mg + ISMN 60 mg
Trial: 11581232
Drug: Cefepime 2
RxNorm normalized name: cefepime 2000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefepime 2 g iv bd
Trial: 11581232
Drug: Cefotaxime 2
RxNorm normalized name: cefotaxime 2000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefotaxime 2 g iv tds
Trial: 9699698
Drug: Psychosocial occupational
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychosocial occupational therapy
Trial: 7931739
Drug: Referral to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Referral to a community physician, monthly 10‐minute work‐site counseling sessions including blood pressure readings, and personalized mailings
Trial: 626273
Drug: Placebo (four
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (four tablets)
Trial: 26559740
Drug: Low-level laser
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-level laser therapy (LLLT) using InGaAlP (660 nm-100 mW-4J/cm2) laser diode.
Trial: 26559740
Drug: Placebo (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (no treatment).
Trial: 26559740
Drug: Low-level laser
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-level laser therapy (LLLT).
Trial: 25226108
Drug: Physical function
RxNorm normalized name: plasma protein fraction Injection [Plasmanate]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical function assessment using the Nottingham Extended Activities of Daily Living
Trial: 17894335
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of apomorphine hydrochloride for 5 days
Trial: 10199772
Drug: Placebo infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo infusion for 5 days
Trial: 17894335
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of apomorphine hydrochloride
Trial: 17894335
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of apomorphine hydrochloride and placebo
Trial: 15041714
Drug: BMS‐275291 (1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BMS‐275291 (1200 mg/day)
Trial: 11585606
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg of T enanthate i.m. weekly for 8 weeks (active group)
Trial: 11585606
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg of sodium chloride i.m. weekly for 8 weeks (placebo group)
Trial: 11585606
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg T enanthate i.m. bi-weekly for 8 weeks (hypogonadal group)
Trial: 177372
Drug: alternating treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: alternating treatment of pivmecillinam and pivampicillin
Trial: 22101426
Drug: Pharmaceutical care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical care intervention focusing on self-management, delivered by a clinical pharmacist, with structured education about COPD and management of its symptoms.
Trial: 19453396
Drug: H5 live
RxNorm normalized name: Typhoid Vaccine Live
DrugBank: Typhoid Vaccine Live (DB11050)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H5 live influenza vaccine (A/17/Duck/Potsdam/86/92 (H5N2)), administered intranasally in two doses 21 days apart.
Trial: 15570576
Drug: Tolterodine (TOL)
DrugBank: Tolterodine (DB01036)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tolterodine (TOL) 4 mg daily for 8 weeks
Trial: 12882824
Drug: Placebo oleic
RxNorm normalized name: Oleic Acid
DrugBank: Oleic Acid (DB04224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Placebo oleic acid dietary supplement
Trial: 3155806
Drug: Ceftriaxone (125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone (125 mg, 0.5 mL injection)
Trial: 3155806
Drug: Spectinomycin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spectinomycin (2 g injection)
Trial: 29248640
Drug: Spironolactone 25
RxNorm normalized name: spironolactone 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spironolactone 25 mg for 6 months (n = 51)
Trial: 30517723
Drug: Ingestion of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ingestion of 500 mL beer
Trial: 30517723
Drug: Ingestion of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ingestion of 500 mL soda
Trial: 30517723
Drug: Ingestion of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ingestion of 500 mL beer and soda
Trial: 27005463
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg anamorelin
Trial: 27005463
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg anamorelin
Trial: 24886581
Drug: Early specific
RxNorm normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early specific cognitive-behavioural psychotherapy (CBT) including stress management and problem solving strategies, with elements of mindfulness-based therapy (MBT) for 14 weeks.
Trial: 16053475
Drug: subcutaneous interferon
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subcutaneous interferon (IFN) beta‐1a, 22 or 44 mug three times weekly
Trial: 11834004
Drug: Diuretics (fusemide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diuretics (fusemide and amiloride)
Trial: 1819543
Drug: Lisuride (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisuride (0.1 mg, 1/2 tablet every 8 hours for 3 months)
Trial: 6128451
Drug: Increased oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increased oral potassium 64 mmol a day
Trial: 25207682
Drug: Intravenous lipid
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous lipid emulsion (20% Intralipid®)
Trial: 22526529
Drug: Triazolam (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triazolam (0.25 and 0.5 mg/70 kg)
Trial: 19106243
Drug: Protein supplementation
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protein supplementation (20 g protein/session) before and after exercise
Trial: 12495901
Drug: rHuG-CSF 10
RxNorm normalized name: rGM-CSF
DrugBank: Sargramostim (DB00020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: rHuG-CSF 10 mg/kg
Trial: 9667102
Drug: KH 1060
RxNorm normalized name: KH-176
DrugBank: Sonlicromanol (DB16333)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KH 1060 ointment
Trial: 11316966
Drug: Ebastine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ebastine (10 mg)
Trial: 31376781
Drug: Question Formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Question Formulation Technique (QFT) intervention
Trial: 27126336
Drug: Ectoine mouth
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ectoine mouth and throat spray
Trial: 27126336
Drug: Saline lozenges
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline lozenges
Trial: 20456625
Drug: Traditional sex
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional sex therapy and/or gingko biloba
Trial: 15760426
Drug: Antifungal therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antifungal therapy for 2 weeks and 3 months
Trial: 15760426
Drug: Anti-retroviral agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-retroviral agents
Trial: 9045329
Drug: Cisplatin 75
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin 75 mg/m2 and paclitaxel 135 mg/m2
Trial: 9045329
Drug: Cisplatin 75
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin 75 mg/m2 and cyclophosphamide 750 mg/m2
Trial: 31617769
Drug: Paracetamol administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol administration by parents after GP consultation
Trial: 31617769
Drug: Paracetamol administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol administration in children aged three to six months
Trial: 31617769
Drug: Paracetamol administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol administration in children aged five to twelve years
Trial: 31617769
Drug: Frequency of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Frequency of paracetamol administration for common infections
Trial: 29402561
Drug: Immediate loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate loading of the implant
Trial: 29402561
Drug: Delayed loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed loading of the implant
Trial: 26659706
Drug: BOC add-on
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BOC add-on therapy at week 12 for patients without cEVR
Trial: 22744547
Drug: Brace treatment
RxNorm normalized name: Brace Relief
DrugBank: Benzocaine (DB01086)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Brace treatment for 18 hours/day
Trial: 22744547
Drug: Brace treatment
RxNorm normalized name: Brace Relief
DrugBank: Benzocaine (DB01086)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Brace treatment for 21 hours/day
Trial: 22744547
Drug: Brace treatment
RxNorm normalized name: Brace Relief
DrugBank: Benzocaine (DB01086)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Brace treatment for 23 hours/day
Trial: 12889696
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (no-gel control)
Trial: 10550566
Drug: Etoposide orally
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Etoposide orally at 50 mg daily and cyclophosphamide orally at 50 mg daily (first cohort)
Trial: 10550566
Drug: Etoposide orally
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Etoposide orally at 50 mg twice daily and cyclophosphamide orally at 50 mg twice daily (second cohort)